statement
Foundayo, its once-daily oral GLP-1 pill orforglipron, met the primary endpoint in the Phase 3 ATTAIN-OSA trial for adults with obesity and moderate-to-severe obstructive sleep apnea.
A statement by Eli Lilly. Statements are as reported by the cited publishers — not verified by DecisionGateway.
Eli Lilly says Foundayo, its once-daily oral GLP-1 pill orforglipron, met the primary endpoint in the Phase 3 ATTAIN-OSA trial for adults with obesity and moderate-to-severe obstructive sleep apnea.
Discussion
Related claims
If regulators accept the sleep-apnea data, Lilly gains a second disease-specific use for an oral obesity drug and a cleaner pitch to patients who do not want injections.MY READ · predictionAt 52 weeks, the apnea-hypopnea index fell by an average 19.1 events per hour with Foundayo versus 3.6 with placebo.Lilly · statementThis widens Foundayo's commercial lane beyond weight loss alone.MY READ · predictionNovo Nordisk announced that the marketing application for its new drug CagriSema (cagrilintide and semaglutide injection) for long-term weight management has been accepted by the National Medical Products Administration.诺和诺德 · statementCagriSema consists of the long-acting amylin receptor agonist cagrilintide and the GLP-1 receptor agonist semaglutide.界面新闻 · statementWhat changes this read: regulators reject the weight-loss-independent analysis, safety or adherence weakens in full publication, or payers restrict coverage despite an approval.MY READ · prediction
More claims by Eli Lilly
No other claims by this actor on record.